ReviewOncoimmunology2016
Trial Watch-Oncolytic viruses and cancer therapy.
Review in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed.
- Dark matter matters: from noncoding RNA regulation to cancer immunity.Oncoimmunology · 2026Review
- Oncolytic virotherapy for cancer: biological mechanisms, clinical advances, and future perspectives.Clinical and experimental medicine · 2026Review
- GM-CSF Armed Oncolytic Adenovirus Enhances T-Cell Infiltration and Suppresses Local and Distal Tumor Growth.Viruses · 2026Article
- Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review).International journal of molecular medicine · 2025Review
- Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.Nature protocols · 2024Review
- Targeting immunogenic cell stress and death for cancer therapy.Nature reviews. Drug discovery · 2024Review
- Digital Pathology for Better Clinical Practice.Cancers · 2024Review
- Principles of risk assessment in colon cancer: immunity is key.Oncoimmunology · 2024Review
- IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma.Nature communications · 2023Article
- Article
- Oncolytic viruses: A novel treatment strategy for breast cancer.Genes & diseases · 2023Review
- Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.Oncoimmunology · 2023Review
- Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer.Cancer medicine · 2022Article
- Immunotherapy of glioblastoma: Recent advances and future prospects.Human vaccines & immunotherapeutics · 2022Review
- Current landscape and perspective of oncolytic viruses and their combination therapies.Translational oncology · 2022Review
- Cowpea Mosaic Virus Outperforms Other Members of the Secoviridae as In Situ Vaccine for Cancer Immunotherapy.Molecular pharmaceutics · 2022Article
- Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy.Frontiers in molecular biosciences · 2022Review
- MicroRNA-detargeting proves more effective thanMolecular therapy oncolytics · 2021Article
- Synergy betweenJournal for immunotherapy of cancer · 2021Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that selectively infect and kill malignant cells while favoring the elicitation of a therapeutically relevant tumor-targeting immune response. During the past few years, great efforts have been dedicated to the development of oncolytic viruses with improved specificity and potency. Such an intense wave of investigation has culminated this year in the regulatory approval by the US Food and Drug Administration (FDA) of a genetically engineered oncolytic viral strain for use in melanoma patients. Here, we summarize recent preclinical and clinical advances in oncolytic virotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.